Observational studyEuropean journal of clinical pharmacology2026
Association between anamorelin therapy and renal function in patients with cancer cachexia: a propensity score-matched retrospective study.
Observational study in European journal of clinical pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThis study investigated the association between anamorelin (ANAM) treatment and longitudinal changes in renal function in patients with cancer cachexia.
methodsThis retrospective, single-centre, observational cohort study reviewed electronic medical records of patients diagnosed with cancer cachexia. Renal function parameters-including blood urea nitrogen (BUN), serum creatinine, and estimated glomerular filtration rate (eGFR)-were compared between patients treated with ANAM and those not receiving ANAM. Propensity score matching was applied to adjust for baseline imbalance in patient characteristics. Renal deterioration was defined as ≥ 10% increase in BUN or ≥ 10% serum creatinine, or ≥ 10% decrease in eGFR. Cox proportional hazards models were applied to BUN, serum creatinine, and eGFR deterioration, respectively.
resultsAfter propensity score matching, ANAM treatment was associated with significantly greater improvements in serum creatinine and eGFR over an 8-week period compared with non-ANAM treatment. Multivariable Cox regression analyses demonstrated that ANAM use was independently associated with a reduction in risk of ≥ 10% increase in serum creatinine and ≥ 10% decrease in eGFR. Longitudinal analyses revealed improvements in renal function markers in the early phase after initiation of ANAM, followed by a gradual return toward baseline levels.
conclusionANAM treatment was associated with improvements in renal function markers and a lower risk of renal function deterioration in patients with cancer cachexia. These findings suggest that ANAM may potentially confer renoprotective effects in addition to its established therapeutic benefits for cachexia.
Indexed as
Identifiers
42298206What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.